Multicomponent crystals made of ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester and an arylpropionic acid
The invention relates to novel multicomponent crystals, to the production thereof, and to the use thereof for treating pain conditions, in particular of unclear genesis, by means of a simultaneous effect on pains which are caused by muscle tension or degenerative joint diseases as well as on pains that are caused by inflammatory processes. The multicomponent crystals according to the invention contain ([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-carbamic acid ethyl ester (flupirtine) and an arylpropionic acid as the sole active ingredient combination and can be produced by dissolving flupirtine and the arylpropionic acid in an inert organic solvent and subsequently crystallizing the multicomponent crystal.
1. Multicomponent crystal, characterized in that it contains as a sole active ingredient combination a combination of:
([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]carbamic acid ethyl ester (flupirtine) and
the arylpropionic acid
(RS)-2-[4-(2-methylpropyl)-phenyl]propanoic acid (ibuprofen),
and further characterized by an X-ray powder diffractogram with a characteristic peak at 2θ=4.7±0.2°.
2. Multicomponent crystal according to claim 1 , additionally characterized by characteristic peaks at 2θ=5.1±0.2 °, 7.7±0.2 °, 9.3±0.2° and 10.4±0.2°.
3. Multicomponent crystal according to claim 1 , additionally characterized by characteristic peaks at 2θ=18.0±0.2 °, 20.6±0.2°, and 27.3±0.2°.
4. Multicomponent crystal according to claim 1 , wherein the arylpropionic acid (RS)-2-[4-(2-methylpropyl)-phenyl]propanoic acid is characterized by a DSC (differential scanning calorimetry) thermogram with a melting endothermal peak in the range of 56 to 70° C. with an onset temperature at 56.9±2 C.° and a signal maximum at 64.7±3° C.
5. Multicomponent crystal, characterized in that it contains as a sole active ingredient combination a combination of:
([2-amino-6-(4-fluoro-benzylamino)-pyridin-3-yl]carbamic acid ethyl ester (flupirtine) and
the arylpropionic acid (+)-(2S)-2-[4-(2-methylpropyl)-phenyl]propanoic acid (dexibuprofen),
and further characterized by an X-ray powder diffractogram with a characteristic peak at 2θ=3.4±0.2°.
6. Multicomponent crystal according to claim 5 , additionally characterized by characteristic peaks at 2θ=8.3±0.2 °, 10.1±0.2 °, 16.7±0.2°, 17.5±0.2°, and 20.7±0.2°.
7. Multicomponent crystal according to claim 5 , additionally characterized by characteristic peaks at 2θ=12.5±0.2 °, 14.4±0.2°, and 24.2±0.2°.
8. Multicomponent crystal according to claim 5 , wherein the arylpropionic acid (+)-(2S)-2-[4-(2-methylpropyl)-phenyl]propanoic acid is characterized by a DSC (differential scanning calorimetry) thermogram with a melt endothermal peak in the range of 73 to 85° C. with an onset temperature at 75.9±2° C. and a signal maximum at 81.4±3° C.
9. Method for preparing a multicomponent crystal according to claim 1 , comprising the steps:
a) dissolving flupirtine and the arylpropionic acid (RS)-2-[4-(2-methylpropyl)-phenyl]propanoic acid (ibuprofen) in a molar ratio of 1.0:0.9 to 1.0 to 1.1 in an inert organic solvent, and
b) crystallizing the multicomponent crystal.
10. Pharmaceutical preparation containing a multicomponent crystal according to claim 1 as active ingredient.
11. Oral pharmaceutical preparation according to claim 10 in the form of a soft capsule.
12. Pharmaceutical preparation according to claim 10 , wherein the pharmaceutical preparation contains 50 to 1,000 mg per administration unit of a multicomponent crystal according to claim 1 as active ingredient.
13. Transdermal pharmaceutical preparation containing a multicomponent crystal according to claim 1 as active ingredient.
14. Method for preparing a pharmaceutical preparation, comprising mixing of a multicomponent crystal according to claim 1 with a solvent on the basis of glycol, a solutizer, and a viscosity-imparting agent such as PVP and introducing the mixture into a soft gelatine capsule.
15. Method for preparing a multicomponent crystal according to claim 5 , comprising the steps:
a) dissolving flupirtine and the arylpropionic acid (+)-(2S)-2-[4-(2-methylpropyl)-phenyl]propanoic acid (dexibuprofen) in a molar ratio of 1.0:0.9 to 1.0 to 1.1 in an inert organic solvent, and
b) crystallizing the multicomponent crystal.
16. Pharmaceutical preparation containing a multicomponent crystal according to claim 5 as active ingredient.
17. Oral pharmaceutical preparation according to claim 16 in the form of a soft capsule.
18. Pharmaceutical preparation according to claim 16 , wherein the pharmaceutical preparation contains 50 to 1,000 mg per administration unit of a multicomponent crystal according to claim 1 as active ingredient.
19. Transdermal pharmaceutical preparation containing a multicomponent crystal according to claim 5 as active ingredient.
20. Method for preparing a pharmaceutical preparation, comprising mixing of a multicomponent crystal according to claim 5 with a solvent on the basis of glycol, a solutizer, and a viscosity-imparting agent such as PVP and introducing the mixture into a soft gelatine capsule.